Role of Fc-mediated antibody function in protective immunity against HIV-1.
about
Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing ActivityCell-targeting antibodies in immunity to EbolaSurvivors Remorse: antibody-mediated protection against HIV-1.Epitope target structures of Fc-mediated effector function during HIV-1 acquisition.Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivoQuantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine developmentPassively acquired antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality.Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1.Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and SubclassesHIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humansFCGR2A and FCGR3A Genotypes in Human Immunodeficiency Virus Mother-to-Child Transmission.Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.Chicken IgY Fc expressed by Eimeria mitis enhances the immunogenicity of E. mitisPerinatal HIV-1 transmission: Fc gamma receptor variability associates with maternal infectiousness and infant susceptibility.The role of Fc receptors in HIV prevention and therapy.Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies.Molecular basis for epitope recognition by non-neutralizing anti-gp41 antibody F240Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodiesCapacity for infectious HIV-1 virion capture differs by envelope antibody specificity.Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.Highly individual patterns of virus-immune IgG effector responses in humans.Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies.Potent In Vivo NK Cell-mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-bispecific and Hexavalent Broadly Neutralizing Fusion Protein.Beyond Viral Neutralization.HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein.Patterns of conserved gp120 epitope presentation on attached HIV-1 virions.Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.High-resolution definition of humoral immune response correlates of effective immunity against HIV.Common helical V1V2 conformations of HIV-1 Envelope expose the α4β7 binding site on intact virions
P2860
Q26782237-AE025225-CEDD-403C-B4F3-E6263D5E42FEQ27318266-89C4E0B2-C437-4445-A966-07C37109B8BCQ28068972-3040D0EA-9066-4D9F-A639-41291213BB9DQ30238730-42CABD81-08CC-44FA-A2CF-3B88E3B8B8D8Q33924272-8D17168F-A571-49DB-A7DD-8555A9AE3A12Q34527478-FC1D4BA3-20E7-47DC-AB6C-85CE6FCC487EQ35072515-A375E036-3034-408E-9FF6-F200555C5E23Q35352866-0AF9F36C-DB5E-4FA2-99CF-8A69574B394AQ35913921-884EEC87-A908-42B9-B588-FC56B1C27F1CQ35952586-7DF49411-8F60-48F6-A950-FD5275D6B4FEQ36118373-70D3EA47-D4D9-4977-A669-7B4E0FB99C96Q36252656-270DD84D-5EE8-455B-B965-882BF2C68065Q36302010-52676836-1BED-4546-BD4D-43CBC1F60F26Q36481483-32B32846-8AAF-4CDF-AEB3-7677258A4FCAQ36715256-B0644355-ABAD-41D8-8EA8-D8F9F9307BF3Q36994530-20C4566E-19BE-4BBC-8EF4-EE3B704637A4Q37113972-920D79B9-CEBC-4E45-A73E-201F58A26A8FQ37184296-D8ECF3C7-AFB4-4F7F-8B4D-13EC708B5304Q37402557-BF18C616-EB4F-4D68-81CA-DF0571409103Q37409262-7A08040D-9DBD-44C8-BBE0-3D1B0808275DQ37523341-E4872680-48D7-4B5B-809F-1EC74333B632Q37621530-052A62B8-D26B-429E-9E77-980AFD39E13CQ37714023-1F873097-284B-4FF5-A41C-CBEDF8AF4978Q38727815-C31DA983-8D57-4571-BA4B-56920E33849EQ38953491-7A5DAF43-7F4F-4002-BB23-4CA4EC557D6CQ38998925-E1BBB3C0-9D3C-4E5C-8543-CF258986C6D8Q40088787-7A2CE538-2F7D-434D-9192-6C83E048E7D4Q40373085-0A3859F8-85B7-4C13-B342-2443B8D77156Q41138686-0C6960DC-AAD0-4D71-8802-D10BD169567EQ47109778-EB127D90-AC46-4117-8FFB-20E572BA74D7Q52673965-3B9E130C-E74F-4CA5-90D2-80B6850C5F0CQ55022148-AA60C9E8-E67F-4B89-84F1-55B17168AB94Q58115616-B45FF875-B9C0-447E-A939-96271ED09E97
P2860
Role of Fc-mediated antibody function in protective immunity against HIV-1.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Role of Fc-mediated antibody function in protective immunity against HIV-1.
@en
type
label
Role of Fc-mediated antibody function in protective immunity against HIV-1.
@en
prefLabel
Role of Fc-mediated antibody function in protective immunity against HIV-1.
@en
P2860
P356
P1433
P1476
Role of Fc-mediated antibody function in protective immunity against HIV-1.
@en
P2093
George K Lewis
P2860
P356
10.1111/IMM.12232
P577
2014-05-01T00:00:00Z